EphA2 Is a Lung Epithelial Cell Receptor for Pneumocystis β-Glucans

Theodore J Kottom1, Kyle Schaefbauer1, Eva M Carmona1

  • 1Thoracic Diseases Research Unit, Departments of Medicine and Biochemistry, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Insights

Ephrin type-A receptor 2 (EphA2) binds Pneumocystis fungal beta-glucans on lung epithelial cells. This interaction triggers inflammation, suggesting EphA2 as a target for Pneumocystis therapies.

Area of Science:

  • Immunology
  • Microbiology
  • Cell Biology

Background:

  • Pneumocystis interactions with myeloid cells are known, but binding to lung epithelial cells is unclear.
  • Ephrin type-A receptor 2 (EphA2) recognizes fungal beta-glucans on lung epithelial cells.

Purpose of the Study:

  • To investigate the mechanism of Pneumocystis binding to lung epithelial cells.
  • To identify specific receptors involved in this interaction.

Main Methods:

  • Investigated EphA2 binding to Pneumocystis beta-glucans.
  • Analyzed EphA2 phosphorylation upon Pneumocystis exposure.
  • Measured interleukin-6 (IL-6) cytokine levels.
  • Utilized EphA2-specific antibodies to block responses.

Main Results:

  • EphA2 binds to Pneumocystis beta-glucans, both isolated and on the organism's surface.
  • Pneumocystis beta-glucan binding induces EphA2 phosphorylation.
  • Interleukin-6 (IL-6) cytokine levels significantly increase in lung epithelial cells exposed to Pneumocystis beta-glucans.
  • EphA2 antibody preincubation blocks the IL-6 response.

Conclusions:

  • EphA2 is identified as a receptor for Pneumocystis on lung epithelial cells.
  • EphA2-mediated signaling contributes to the inflammatory response.
  • EphA2 presents a potential target for therapeutic interventions against Pneumocystis infections.